<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SAVELLA - milnacipran hydrochloride tablet, film coated </strong><br>STAT RX USA LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Savella safely and effectively. See full prescribing information for Savella.<br>Savella® (milnacipran HCl) Tablets<br>Initial U.S. Approval: 2009
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc"><li><span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, thinking and behavior in children, adolescents, and young adults taking antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Savella is not approved for use in pediatric patients (<a href="#s14">5.1</a>)</span></li></ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc"><li><span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, thinking and behavior in children, adolescents, and young adults taking antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Savella is not approved for use in pediatric patients (<a href="#s14">5.1</a>)</span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Savella® is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (<a href="#s2">1</a>) </p>
<p class="Highlighta">Savella is not approved for use in pediatric patients (<a href="#s14">5.1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Administer Savella in two divided doses per day (<a href="#s4">2.1</a>)</li>
<li>Based on efficacy and tolerability, dosing may be titrated according to the following schedule (<a href="#s4">2.1</a>):<br>Day 1: 12.5 mg once<br>Days 2-3: 25 mg/day (12.5 mg twice daily)<br>Days 4-7: 50 mg/day (25 mg twice daily)<br>After Day 7: 100 mg/day (50 mg twice daily)</li>
<li>Recommended dose is 100 mg/day (<a href="#s4">2.1</a>)</li>
<li>May be increased to 200 mg/day based on individual patient response (<a href="#s4">2.1</a>)</li>
<li>Dose should be adjusted in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#s5">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 12.5 mg, 25 mg, 50 mg, 100 mg (<a href="#s9">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Use of monoamine oxidase inhibitors concomitantly or in close temporal proximity (<a href="#s11">4.1</a>)</li>
<li>Use in patients with uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<a href="#s12">4.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Suicidality: Monitor for worsening of <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> risk (<a href="#s14">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>: <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> has been reported with SNRIs and SSRIs.  Concomitant use of serotonergic drugs is not recommended (<a href="#s15">5.2</a>)</li>
<li>Elevated blood pressure and heart rate: Cases have been reported with Savella. Monitor blood pressure and heart rate prior to initiating treatment with Savella and periodically throughout treatment (<a href="#s16">5.3</a>, <a href="#s17">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: Cases have been reported with Savella therapy. Prescribe Savella with care in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder. (<a href="#s18">5.5</a>)</li>
<li>Hepatotoxicity: More patients treated with Savella than with placebo experienced mild elevations of ALT and AST. Rarely, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> has been reported in patients treated with Savella. Avoid concomitant use of Savella in patients with substantial alcohol use or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> (<a href="#s19">5.6</a>)</li>
<li>Discontinuation: Withdrawal symptoms have been reported in patients when discontinuing treatment with Savella. A gradual dose reduction is recommended   (<a href="#s20">5.7</a>)</li>
<li>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: Savella may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of Savella and NSAIDs, aspirin, or other drugs that affect coagulation. (<a href="#s22">5.9</a>)</li>
<li>Male patients with a history of obstructive uropathies may experience higher rates of genitourinary adverse events (<a href="#s24">5.11</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most frequently occurring adverse reactions (≥ 5% and greater than placebo) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, palpations, <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (<a href="#s31">6.3</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Forest Pharmaceuticals, Inc., at (800) 678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Savella is unlikely to be involved in clinically significant pharmacokinetic drug interactions (<a href="#s36">7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacodynamic interactions</span> of Savella with other drugs can occur (<a href="#s36">7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy and nursing mothers: Use only if the potential benefit justifies the potential risk to the fetus or child. (<a href="#s39">8.1</a>, <a href="#s43">8.3</a>)</li>
<li>To enroll in the Savella Pregnancy Registry call 1-877-643-3010 (toll free) or download data forms from the registry website: www.savellapregnancyregistry.com (<a href="#s39">8.1</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Discontinuing Savella</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Switching patients to or from a Monoamine Oxidase Inhibitor (MAOI)</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Monoamine Oxidase Inhibitors</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Uncontrolled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-Like Reactions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Effects on Blood Pressure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Effects on Heart Rate</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Hepatotoxicity</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Discontinuation of Treatment with Savella</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Patients with a History of <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Concomitant Use with Alcohol</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> to FD&amp;C Yellow No. 5</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Data Sources</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Adverse Reactions Leading to Discontinuation</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Most Common Adverse Reactions</a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Weight Changes</a></h2>
<h2><a href="#section-6.5" class="toc">6.5 Genitourinary Adverse Reactions in Males</a></h2>
<h2><a href="#section-6.6" class="toc">6.6 Other Adverse Reactions Observed During Clinical Trials of Savella in <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></a></h2>
<h2><a href="#section-6.7" class="toc">6.7 Postmarketing Spontaneous Reports</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Monoamine Oxidase Inhibitors
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Serotonergic Drugs
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Triptans
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Catecholamines
</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 CNS-active drugs
</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Clinically Important Interactions with Select Cardiovascular Agents
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-12.4" class="toc">12.4 Pharmacokinetics in Special Populations</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Information in Medication Guide</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Effect on Blood Pressure and Pulse</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Ability to Drive and Use Machinery</a></h2>
<h2><a href="#section-16.7" class="toc">17.7 Alcohol</a></h2>
<h2><a href="#section-16.8" class="toc">17.8 Discontinuation</a></h2>
<h2><a href="#section-16.9" class="toc">17.9 Pregnancy</a></h2>
<h2><a href="#section-16.10" class="toc">17.10 Nursing</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Savella is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other psychiatric disorders. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Anyone considering the use of such drugs in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and certain other psychiatric disorders are themselves associated with increases in the risk of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. Patients of all ages who are started on Savella should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Savella is not approved for use in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. Savella is not approved for use in pediatric patients [</span><span class="Bold Italics">see Warnings and Precautions (<a href="#s14">5.1</a>), Use in Specific Populations (<a href="#s44">8.4</a>)</span><span class="Bold">]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Savella is indicated for the management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>.</p>
<p>Savella is not approved for use in pediatric patients [<span class="Italics">see Use in Specific Populations (<a href="#s44">8.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Savella is given orally with or without food.</p>
<p>Taking Savella with food may improve the tolerability of the drug.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">The recommended dose of Savella is 100 mg/day (50 mg twice daily).</p>
<p>Based on efficacy and tolerability dosing may be titrated according to the following schedule:<br><span class="Bold">Day 1:</span> 12.5 mg once<br><span class="Bold">Days 2-3:</span> 25 mg/day (12.5 mg twice daily)<br><span class="Bold">Days 4-7:</span> 50 mg/day (25 mg twice daily)<br><span class="Bold">After Day 7:</span> 100 mg/day (50 mg twice daily)</p>
<p>Based on individual patient response, the dose may be increased to 200 mg/day (100 mg twice daily).</p>
<p>Doses above 200 mg/day have not been studied.</p>
<p>Savella should be tapered and not abruptly discontinued after extended use <span class="Italics">[see Discontinuing Savella (<a href="#s7">2.4</a>) and Warnings and Precautions (<a href="#s20">5.7</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">No dosage adjustment is necessary in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Savella should be used with caution in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. For patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (indicated by an estimated creatinine clearance of 5-29 mL/min), the maintenance dose should be reduced by 50% to 50 mg/day (25 mg twice daily).</p>
<p>Based on individual patient response, the dose may be increased to 100 mg/day (50 mg twice daily).</p>
<p>Savella is not recommended for patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">No dosage adjustment is necessary for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>As with any drug, caution should be exercised in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Discontinuing Savella</h2>
<p class="First">Withdrawal symptoms have been observed in clinical trials following discontinuation of milnacipran, as with other serotonin and norepinephrine re-uptake inhibitors (SNRIs) and selective serotonin re-uptake inhibitors (SSRIs). Patient should be monitored for these symptoms when discontinuing treatment. Savella should be tapered and not abruptly discontinued after extended use [<span class="Italics">see Warnings and Precautions (<a href="#s20">5.7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Switching patients to or from a Monoamine Oxidase Inhibitor (MAOI)</h2>
<p class="First">At least 14 days should elapse between discontinuation of a MAOI and initiation of therapy with Savella. In addition, at least 5 days should be allowed after stopping Savella before starting a MAOI [<span class="Italics">see Contraindications (<a href="#s11">4.1</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s9"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Film-coated, immediate release tablets in four strengths: 12.5 mg, 25 mg, 50 mg, and 100 mg of milnacipran hydrochloride.</p>
<p>12.5 mg tablets are round, pink, "F" on one side, "L" on the reverse;</p>
<p>25 mg tablets are round, white, "FL" on one side, "25" on the reverse;</p>
<p>50 mg tablets are oval, green, "FL" on one side, "50" on the reverse;</p>
<p>100 mg tablets are oval, blue, "FL" on one side, "100" on the reverse</p>
<p>[<span class="Italics">see Description</span> (<a href="#s52">11</a>) <span class="Italics">and How Supplied/ Storage and Handling (<a href="#s77">16</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Monoamine Oxidase Inhibitors</h2>
<p class="First">Concomitant use of Savella in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated. In patients receiving a serotonin reuptake inhibitor in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions including <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuations of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> that include extreme <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> progressing to <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. These reactions have also been reported in patients who have recently discontinued serotonin reuptake inhibitors and have been started on an MAOI. Some cases presented with features resembling <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>. The effects of combined use of Savella and MAOIs have not been evaluated in humans. Therefore, it is recommended that Savella should not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. Similarly, at least 5 days should be allowed after stopping Savella before starting an MAOI [see <span class="Italics">Dosage and Administration (<a href="#s8">2.5</a>), Warnings and Precautions</span> (<a href="#s15">5.2</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Uncontrolled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">In clinical trials, Savella was associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> has been reported with other dual reuptake inhibitors of norepinephrine and serotonin; therefore, do not use Savella in patients with uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s13"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Savella is a selective serotonin and norepinephrine re-uptake inhibitor (SNRI), similar to some drugs used for the treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other psychiatric disorders.</p>
<p>Patients, both adult and pediatric, with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other psychiatric disorders may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking these medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants, including drugs that inhibit the reuptake of norepinephrine and/or serotonin, may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment.</p>
<p>In the placebo-controlled clinical trials of adults with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>, among the patients who had a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> at treatment initiation, the incidence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> was 0.5% in patients treated with placebo, 0% in patients treated with Savella 100 mg/day, and 1.3% in patients treated with Savella 200 mg/day. No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in the short-term or longer-term (up to 1 year) <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> trials.</p>
<p>Pooled analyses of short-term placebo-controlled trials of drugs used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with these drugs compared to placebo in adults beyond age 24; there was a reduction in suicidality risk with antidepressants compared to placebo in adults age 65 and older.</p>
<p>The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 drugs used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk of differences (drug versus placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in <a href="#t1">Table 1</a>.</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1. Risk Differences (Drug – Placebo) in the number of Cases of Suicidality, per 1000 patients treated</span></caption>
<col align="left" width="16.100%">
<col align="left" width="83.900%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Age Range</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&lt; 18</td>
<td class="Botrule Rrule" align="left" valign="top">14 additional cases</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">18-24</td>
<td class="Botrule Rrule" align="left" valign="top">5 additional cases</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Decreases Compared to Placebo</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">25-64</td>
<td class="Botrule Rrule" align="left" valign="top">1 fewer case</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">≥ 65</td>
<td class="Botrule Rrule" align="left" valign="top">6 fewer cases</td>
</tr>
</tbody>
</table>
<p>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold">All patients being treated with drugs inhibiting the reuptake of norepinephrine and/or serotonin for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span></p>
<p>The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, have been reported in adult and pediatric patients being treated with drugs inhibiting the reuptake of norepinephrine and/or serotonin for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who may experience worsening <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe or abrupt in onset, or were not part of the patient's presenting symptoms.</p>
<p>If the decision has been made to discontinue treatment due to worsening <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> or emergent suicidality, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can produce withdrawal symptoms <span class="Italics">[see Dosage and Administration—Recommended Dosing (<a href="#s4">2.1</a>), Dosage—Discontinuing Savella (</span><a href="#s7">2.4</a>), and <span class="Italics">Warnings and Precautions—Discontinuation of Treatment with Savella (</span><a href="#s20">5.7</a><span class="Italics">)].</span></p>
<p><span class="Bold">Families and caregivers of patients being treated with drugs inhibiting the reuptake of norepinephrine and/or serotonin for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Savella should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-Like Reactions</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including Savella, but particularly with concomitant use of serotonergic drugs (including triptans), with drugs which impair metabolism of serotonin (including MAOIs) or with antipsychotics or other dopamine antagonists. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>) <span class="Italics">[see Drug Interactions (<a href="#s36">7</a>)]</span>. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>, in its most severe form can resemble <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, which includes <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuation of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>. Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or NMS-like signs and symptoms.</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The concomitant use of Savella with MAOIs is contraindicated <span class="Italics">[see Contraindications (<a href="#s11">4.1</a>)].</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>If concomitant treatment of Savella with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases <span class="Italics">[see Drug Interactions (<a href="#s36">7</a>)].</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The concomitant use of Savella with serotonin precursors (such as tryptophan) is not recommended <span class="Italics">[see Drug Interactions (<a href="#s36">7</a>)]</span>. Treatment with Savella and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Effects on Blood Pressure</h2>
<p class="First">Inhibition of the reuptake of norepinephrine (NE) and serotonin (5-HT) can lead to cardiovascular effects. SNRIs, including Savella, have been associated with reports of increase in blood pressure.</p>
<p>In a double-blind, placebo-controlled clinical pharmacology study in healthy subjects designed to evaluate the effects of milnacipran on various parameters, including blood pressure at supratherapeutic doses, there was evidence of mean increases in supine blood pressure at doses up to 300 mg twice daily (600 mg/day). At the highest 300 mg twice daily dose, the mean increase in systolic blood pressure was up to 8.1 mm Hg for the placebo group and up to 10.0 mm Hg for the Savella treated group over the 12 hour steady state dosing interval. The corresponding mean increase in diastolic blood pressure over this interval was up to 4.6 mm Hg for placebo and up to 11.5 mm Hg for the Savella treated group.</p>
<p>In the 3-month placebo-controlled <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> clinical trials, Savella treatment was associated with mean increases of up to 3.1 mm Hg in systolic blood pressure (SBP) and diastolic blood pressure (DBP) [<span class="Italics">see Adverse Reactions (<a href="#s31">6.3</a>)</span>].</p>
<p>In the placebo-controlled trials, among <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> patients who were non-hypertensive at baseline, approximately twice as many patients in the Savella treatment arms became hypertensive at the end of the study (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) compared with the placebo patients: 7.2% of patients in the placebo arm versus 19.5% of patients treated with Savella 100 mg/day and 16.6% of patients treated with Savella 200 mg/day. Among patients who met systolic criteria for pre-<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> at baseline (SBP 120-139 mmHg), more patients became hypertensive at the end of the study in the Savella treatment arms than placebo: 9% of patients in the placebo arm versus 14% in both the Savella 100 mg/day and the Savella 200 mg/day treatment arms.</p>
<p>Among <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> patients who were hypertensive at baseline, more patients in the Savella treatment arms had a &gt;15 mmHg increase in SBP than placebo at the end of the study: 1% of patients in the placebo arm versus 7% in the Savella 100 mg/day and 2% in the Savella 200 mg/day treatment arms. Similarly, more patients who were hypertensive at baseline and were treated with Savella had DBP increases &gt; 10 mmHg than placebo at the end of study: 3% of patients in the placebo arm versus 8% in the Savella 100 mg/day and 6% in the Savella 200 mg/day treatment arms.</p>
<p>Sustained increases in SBP (increase of ≥ 15 mmHg on three consecutive post-baseline visits) occurred in 2% of placebo patients versus 9% of patients receiving Savella 100 mg/day and 6% of patients receiving Savella 200 mg/day. Sustained increases in DBP (increase of ≥ 10 mmHg on 3 consecutive post-baseline visits) occurred in 4% of patients receiving placebo versus 13% of patients receiving Savella 100 mg/day and 10% of patients receiving Savella 200 mg/day.</p>
<p>Sustained increases in blood pressure could have adverse consequences. Cases of elevated blood pressure requiring immediate treatment have been reported.</p>
<p>Concomitant use of Savella with drugs that increase blood pressure and pulse has not been evaluated and such combinations should be used with caution <span class="Italics">[see Drug Interactions (<a href="#s36">7</a>)].</span></p>
<p>Effects of Savella on blood pressure in patients with significant <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or cardiac disease have not been systematically evaluated. Savella should be used with caution in these patients.</p>
<p>Blood pressure should be measured prior to initiating treatment and periodically measured throughout Savella treatment. Pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and other cardiovascular disease should be treated before starting therapy with Savella. For patients who experience a sustained increase in blood pressure while receiving Savella, either dose reduction or discontinuation should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Effects on Heart Rate</h2>
<p class="First">SNRIs have been associated with reports of increase in heart rate.</p>
<p>In clinical trials, relative to placebo, Savella treatment was associated with mean increases in pulse rate of approximately 7 to 8 beats per minute [<span class="Italics">see Adverse Reactions (<a href="#s30">6.2</a>,<a href="#s31">6.3</a>)</span>].</p>
<p>Increases in pulse ≥ 20 bpm occurred more frequently in Savella-treated patients when compared to placebo: 0.3% in the placebo arm versus 8% in the Savella 100 mg/day and 8% in the 200 mg/day treatment arms. The effect of Savella on heart rate did not appear to increase with increasing dose.</p>
<p>Savella has not been systematically evaluated in patients with a cardiac rhythm disorder.</p>
<p>Heart rate should be measured prior to initiating treatment and periodically measured throughout Savella treatment. Pre-existing <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span> and other cardiac disease should be treated before starting therapy with Savella. For patients who experience a sustained increase in heart rate while receiving Savella, either dose reduction or discontinuation should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">Savella has not been systematically evaluated in patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder. In clinical trials evaluating Savella in patients with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have not been reported. However, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been reported infrequently in patients treated with Savella for disorders other than <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>. Savella should be prescribed with care in patients with a history of a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Hepatotoxicity</h2>
<p class="First">In the placebo-controlled <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> trials, increases in the number of patients treated with Savella with mild elevations of ALT or AST (1-3 times the upper limit of normal, ULN) were observed. Increases in ALT were more frequently observed in the patients treated with Savella 100 mg/day (6%) and Savella 200 mg/day (7%), compared to the patients treated with placebo (3%). One patient receiving Savella 100 mg/day (0.2%) had an increase in ALT greater than 5 times the upper limit of normal but did not exceed 10 times the upper limit of normal. Increases in AST were more frequently observed in the patients treated with Savella 100 mg/day (3%) and Savella 200 mg/day (5%) compared to the patients treated with placebo (2%).</p>
<p>The increases of bilirubin observed in the <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> clinical trials were not clinically significant.</p>
<p>No case met the criteria of elevated ALT &gt; 3x ULN and associated with an increase in bilirubin ≥ 2x ULN.</p>
<p>There have been cases of increased liver enzymes and reports of severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with milnacipran from foreign postmarketing experience. In the cases of severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> there were significant underlying clinical conditions and/or the use of multiple concomitant medications. Because of underreporting, it is impossible to provide an accurate estimate of the true incidence of these reactions.</p>
<p>Savella should be discontinued in patients who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other evidence of liver dysfunction. Treatment with Savella should not be resumed unless another cause can be established.</p>
<p>Savella should ordinarily not be prescribed to patients with substantial alcohol use or evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Discontinuation of Treatment with Savella</h2>
<p class="First">Withdrawal symptoms have been observed in clinical trials following discontinuation of milnacipran, as with other SNRIs and SSRIs.</p>
<p>During marketing of milnacipran, and other SNRIs and SSRIs, there have been spontaneous reports of adverse events indicative of withdrawal and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> occurring upon discontinuation of these drugs, particularly when discontinuation is abrupt. The adverse events include the following: dysphoric mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">electric shock sensations</span>), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Although these events are generally self-limiting, some have been reported to be severe.</p>
<p>Patients should be monitored for these symptoms when discontinuing treatment with Savella. Savella should be tapered and not abruptly discontinued after extended use. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate <span class="Italics">[see Dosage and Administration (<a href="#s7">2.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> may occur as a result of treatment with SSRIs and SNRIs, including Savella. In many cases, this <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with SNRIs, SSRIs, or Savella. Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [<span class="Italics">see Geriatric Use (<a href="#s45">8.5</a>)</span>]. Discontinuation of Savella should be considered in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. Signs and symptoms associated with more severe and/or acute cases have included <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">SSRIs and SNRIs, including Savella, may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anti-coagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events related to SSRIs and SNRIs use have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>.</p>
<p>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of Savella and NSAIDs, aspirin, or other drugs that affect coagulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></h2>
<p class="First">No activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> was reported in the clinical trials evaluating effects of Savella in patients with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>. However those clinical trials excluded patients with current major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span>. Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> and <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> have been reported in patients with mood disorders who were treated with other similar drugs for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. As with these other agents, Savella should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Patients with a History of <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></h2>
<p class="First">Because of their noradrenergic effect, SNRIs including Savella, can affect urethral resistance and micturition. In the controlled <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> trials, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span> occurred more frequently in patients treated with Savella (1%) than in placebo-treated patients (0.5%). Caution is advised in use of Savella in patients with a history of <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, notably in male patients with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span>, and other lower urinary tract obstructive disorders. Male patients are more prone to genitourinary adverse effects, such as <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span> or <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, and may experience <span class="product-label-link" type="condition" conceptid="4270932" conceptname="Pain in testicle">testicular pain</span> or <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorders</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> has been reported in association with SNRIs and Savella; therefore, Savella should be used cautiously in patients with controlled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p>Do not use Savella in patients with Uncontrolled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> <span class="Italics">[see Contraindications (<a href="#s12">4.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Concomitant Use with Alcohol</h2>
<p class="First">In clinical trials, more patients treated with Savella developed elevated transaminases than did placebo treated patients [see <span class="Italics">Warnings and Precautions (<a href="#s19">5.6</a>)</span>]. Because it is possible that milnacipran may aggravate pre-existing liver disease, Savella should not be prescribed to patients with substantial alcohol use or evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> to FD&amp;C Yellow No. 5</h2>
<p class="First">This product contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in susceptible persons. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s28"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Data Sources</h2>
<p class="First">Savella was evaluated in three double-blind placebo-controlled trials involving 2209 <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> patients (1557 patients treated with Savella and 652 patients treated with placebo) for a treatment period up to 29 weeks.</p>
<p>The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Adverse Reactions Leading to Discontinuation</h2>
<p class="First">In placebo-controlled trials in patients with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>, 23% of patients treated with Savella 100 mg/day, 26% of patients treated with Savella 200 mg/day discontinued prematurely due to adverse reactions, compared to 12% of patients treated with placebo. The adverse reactions that led to withdrawal in ≥ 1% of patients in the Savella treatment group and with an incidence rate greater than that in the placebo treatment group were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (milnacipran 6%, placebo 1%), <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> (milnacipran 3%, placebo 1%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (milnacipran 2%, placebo 0%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (milnacipran 1%, placebo 0%), <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span> (milnacipran 1%, placebo 0%), and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span> (milnacipran 1%, placebo 0%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (milnacipran 1%, placebo 0%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (milnacipran 1% and placebo 0.5%). Discontinuation due to adverse reactions was generally more common among patients treated with Savella 200 mg/day compared to Savella 100 mg/day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Most Common Adverse Reactions</h2>
<p class="First">In the placebo-controlled <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> patient trials the most frequently occurring adverse reaction in clinical trials was <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. The most common adverse reactions (incidence ≥ 5% and twice placebo) in patients treated with Savella were <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p><a href="#t2">Table 2</a> lists all adverse reactions that occurred in at least 2% of patients treated with Savella at either 100 or 200 mg/day and at an incidence greater than that of placebo.</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2. Treatment-Emergent Adverse Reaction Incidence in Placebo Controlled Trials in <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> Patients (Events Occurring in at Least 2% of All Savella-Treated Patients and Occurring More Frequently in Either Savella Treatment Group Than in the Placebo Treatment Group)</span></caption>
<col align="left" width="32.773%">
<col align="left" width="16.797%">
<col align="left" width="16.817%">
<col align="left" width="16.797%">
<col align="left" width="16.817%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">System Organ Class– </span><br><span class="Bold">Preferred Term</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Savella </span><br><span class="Bold">100 mg/day </span><br><span class="Bold">(n = 623) %</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Savella </span><br><span class="Bold">200 mg/day</span><br><span class="Bold">(n = 934) %</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">All Savella </span><br><span class="Bold">(n = 1557) %</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo </span><br><span class="Bold">(n = 652) %</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
<td class="Botrule Rrule" align="center" valign="middle">7</td>
<td class="Botrule Rrule" align="center" valign="middle">7</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="middle">35</td>
<td class="Botrule Rrule" align="center" valign="middle">39</td>
<td class="Botrule Rrule" align="center" valign="middle">37</td>
<td class="Botrule Rrule" align="center" valign="middle">20</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">General Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Botrule Rrule" align="center" valign="middle">7</td>
<td class="Botrule Rrule" align="center" valign="middle">6</td>
<td class="Botrule Rrule" align="center" valign="middle">6</td>
<td class="Botrule Rrule" align="center" valign="middle">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Investigations</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">Heart rate increased</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Blood pressure  increased</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center" valign="top">19</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="middle">11</td>
<td class="Botrule Rrule" align="center" valign="middle">10</td>
<td class="Botrule Rrule" align="center" valign="middle">10</td>
<td class="Botrule Rrule" align="center" valign="middle">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">Tension headache</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Botrule Rrule" align="center" valign="middle">5</td>
<td class="Botrule Rrule" align="center" valign="middle">3</td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Botrule Rrule" align="center" valign="middle">3</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flush</span></td>
<td class="Botrule Rrule" align="center" valign="middle">11</td>
<td class="Botrule Rrule" align="center" valign="middle">12</td>
<td class="Botrule Rrule" align="center" valign="middle">12</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Weight Changes</h2>
<p class="First">In placebo-controlled <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> clinical trials, patients treated with Savella for up to 3 months experienced a mean <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of approximately 0.8 kg in both the Savella 100 mg/day and the Savella 200 mg/day treatment groups, compared with a mean <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of approximately 0.2 kg in placebo-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-6.5"></a><p></p>
<h2>6.5 Genitourinary Adverse Reactions in Males</h2>
<p class="First">In the placebo-controlled <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> studies, the following treatment-emergent adverse reactions related to the genitourinary system were observed in at least 2% of male patients treated with Savella, and occurred at a rate greater than in placebo-treated male patients: <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">ejaculation failure</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span>, <span class="product-label-link" type="condition" conceptid="4071874" conceptname="Pain in scrotum">scrotal pain</span>, <span class="product-label-link" type="condition" conceptid="4270932" conceptname="Pain in testicle">testicular pain</span>, <span class="product-label-link" type="condition" conceptid="4339088" conceptname="Testicular mass">testicular swelling</span>, <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4280509" conceptname="Pain in urethra">urethral pain</span>, and <span class="product-label-link" type="condition" conceptid="195926" conceptname="Slowing of urinary stream">urine flow decreased</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-6.6"></a><p></p>
<h2>6.6 Other Adverse Reactions Observed During Clinical Trials of Savella in <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></h2>
<p class="First">Following is a list of frequent (those occurring on one or more occasions in at least 1/100 patients) treatment-emergent adverse reactions reported from 1824 <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> patients treated with Savella for periods up to 68 weeks. The listing does not include those events already listed in <a href="#t1">Table 1</a>, those events for which a drug cause was remote, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life threatening.</p>
<p>Adverse reactions are categorized by body system and listed in order of decreasing frequency. Adverse reactions of major clinical importance are described in the <span class="Italics">Warnings and Precautions</span> section (<a href="#s13">5</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> - <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span></p>
<p>General Disorders - <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> - <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span></p>
<p>Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications - <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span></p>
<p>Investigations - <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span> or increased</p>
<p>Metabolism and Nutrition Disorders - <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> - <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span></p>
<p>Psychiatric Disorders - <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, stress</p>
<p><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span> - <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-6.7"></a><p></p>
<h2>6.7 Postmarketing Spontaneous Reports</h2>
<p class="First">The following additional adverse reactions have been identified from spontaneous reports of Savella received worldwide. These adverse reactions have been chosen for inclusion because of a combination of seriousness, frequency of reporting, or potential causal connection to Savella. However, because these adverse reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events include:</p>
<p>Blood and Lymphatic System Disorders - <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span> - <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span></p>
<p><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span> - <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">accommodation disorder</span></p>
<p><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span> - <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span></p>
<p>Hepatobiliary Disorders - <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p>Metabolism and Nutrition Disorders - <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span></p>
<p>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span> - <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> - <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> (including <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>), <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span></p>
<p>Psychiatric Disorders - <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span></p>
<p>Renal and Urinary Disorders - <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span></p>
<p>Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span> - <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span></p>
<p><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span> - <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens Johnson syndrome</span></p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span> - <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s36"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Milnacipran undergoes minimal CYP450 related metabolism, with the majority of the dose excreted unchanged in urine (55%), and has a low binding to plasma proteins (13%). In vitro and in vivo studies showed that Savella is unlikely to be involved in clinically significant pharmacokinetic drug interactions <span class="Italics">[see Pharmacokinetics in Special Populations (<a href="#s59">12.4</a>)]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="j2"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Monoamine Oxidase Inhibitors
</h2>
<p class="First"><span class="Italics">[See Contraindications (<a href="#s11">4.1</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="j3"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Serotonergic Drugs
</h2>
<p class="First">Due to the mechanism of action of SNRIs and SSRIs, including Savella, and the potential for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) – like reactions, caution is advised when Savella is co-administered with other drugs that may affect the serotonergic neurotransmitter systems.  This includes drugs such as triptans, lithium, tryptophan, antipsychotics and dopamine antagonists.
</p>
<p>Co-administration of Savella with other inhibitors of serotonin re-uptake may result in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and coronary artery <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, through additive serotonergic effects.  Concomitant use of Savella with other SSRIs, SNRIs, or tryptophan is not recommended <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="j4"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Triptans
</h2>
<p class="First">There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with use of an SSRI and a triptan.  If concomitant treatment of Savella with a triptan is clinically warranted, careful observation of the patient is advised, , particularly during treatment initiation and dose increases. <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.2</a>)</span>]
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="j5"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Catecholamines
</h2>
<p class="First">Savella inhibits the reuptake of norepinephrine. Therefore concomitant use of Savella with epinephrine and norepinephrine may be associated with paroxysmal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and possible <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> [<span class="Italics">see Warnings and Precautions – Effects on Blood Pressure (<a href="#s16">5.3</a>)</span> and <span class="Italics">Effects on Heart Rate (<a href="#s17">5.4</a>)</span>]
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="j6"></a><a name="section-7.5"></a><p></p>
<h2>7.5 CNS-active drugs
</h2>
<p class="First">Given the primary CNS effects of Savella, caution should be used when it is taken in combination with other centrally acting drugs, including those with a similar mechanism of action.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="j7"></a><a name="section-7.5.1"></a><p></p>
<p class="First"><span class="Italics">Clomipramine:</span> In a drug-drug interaction study, an increase in <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> was observed in patients who switched from clomipramine to Savella.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="j8"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Clinically Important Interactions with Select Cardiovascular Agents
</h2>
<p class="First">Digoxin: Use of Savella concomitantly with digoxin may be associated with potentiation of adverse hemodynamic effects. <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> have been reported in combination therapy with intravenously administered digoxin (1 mg). Co-administration of Savella and intravenous digoxin should be avoided [<span class="Italics">see Warnings and Precautions (<a href="#s16">5.3</a>, <a href="#s17">5.4</a>)</span>]
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="j9"></a><a name="section-7.6.1"></a><p></p>
<h3>
<span class="Italics">Clonidine:</span> Because Savella inhibits norepinephrine reuptake, co-administration with clonidine may inhibit clonidine's anti-hypertensive effect.?
</h3>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s38"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s39"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C</p>
<p>Milnacipran increased the incidence of dead fetuses in utero in rats at doses of 5 mg/kg/day (0.25 times the MRHD on a mg/m<span class="Sup">2</span> basis). Administration of milnacipran to mice and rabbits during the period of organogenesis did not result in embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at doses up to 125 mg/kg/day in mice (3 times the maximum recommended human dose [MRHD] of 200 mg/day on a mg/m<span class="Sup">2</span> basis) and up to 60 mg/kg/day in rabbits (6 times the MRHD of 200 mg/day on a mg m<span class="Sup">2</span> basis). In rabbits, the incidence of the skeletal variation, extra single rib, was increased following administration of milnacipran at 15 mg/kg/day during the period of organogenesis.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Savella should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline">To provide information regarding the exposure to Savella during pregnancy, Physicians are advised to recommend that pregnant patients taking Savella enroll in the Savella Pregnancy Registry. Enrollment is voluntary and may be initiated by pregnant patients or their healthcare providers by contacting the registry at 1-877-643-3010 or by email at </span>registries@kendle.com<span class="Underline">. Data forms may also be downloaded from the registry website at </span>www.savellapregnancyregistry.com<span class="Underline">.</span></p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s41"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Underline">Nonteratogenic Effects</span></p>
<p>Neonates exposed to dual reuptake inhibitors of serotonin and norepinephrine, or selective serotonin reuptake inhibitors late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of these classes of drugs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> [<span class="Italics">see Warnings and Precautions (<a href="#s15">5.2</a>)</span>].</p>
<p>In rats, a decrease in pup body weight and viability on postpartum day 4 were observed when milnacipran, at a dose of 5 mg/kg/day (approximately 0.2 times the MRHD on a mg/m<span class="Sup">2</span> basis), was administered orally to rats during late gestation. The no-effect dose for maternal and offspring toxicity was 2.5 mg/kg/day (approximately 0.1 times the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s42"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of milnacipran on labor and delivery is unknown. The use of Savella during labor and delivery is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s43"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">There are no adequate and well-controlled studies in nursing mothers. It is not known if milnacipran is excreted in human milk. Studies in animals have shown that milnacipran or its metabolites are excreted in breast milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from milnacipran, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. Because the safety of Savella in infants is not known, nursing while on Savella is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s44"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of Savella in a <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> pediatric population below the age of 17 have not been established [<span class="Italics">see <a href="#s1">Box Warning</a></span> and <span class="Italics">Warnings and Precautions (<a href="#s14">5.1</a>)</span>]. The use of Savella is not recommended in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s45"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In controlled clinical studies of Savella, 402 patients were 60 years or older, and no overall differences in safety and efficacy were observed between these patients and younger patients.</p>
<p>In view of the predominant excretion of unchanged milnacipran via kidneys and the expected decrease in renal function with age renal function should be considered prior to use of Savella in the elderly [<span class="Italics">see Dosage and Administration (<a href="#s5">2.2</a>)</span>].</p>
<p>SNRIs, SSRIs, and Savella, have been associated with cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse event [<span class="Italics">see Warnings and Precautions (<a href="#s21">5.8</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s46"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="s47"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Milnacipran is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="s48"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Milnacipran did not produce behavioral signs indicative of abuse potential in animal or human studies.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="s49"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Milnacipran produces physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, as evidenced by the emergence of withdrawal symptoms following drug discontinuation, similar to other SNRIs and SSRIs. These withdrawal symptoms can be severe. Thus, Savella should be tapered and not abruptly discontinued after extended use. [see <span class="Italics">Section <a href="#s20">5.7</a> Discontinuation of Treatment with Savella</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s50"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is limited clinical experience with Savella <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in humans. In clinical trials, cases of acute ingestions up to 1000 mg, alone or in combination with other drugs, were reported with none being fatal.</p>
<p>In postmarketing experience, fatal outcomes have been reported for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span> primarily involving multiple drugs but also with Savella only. The most common signs and symptoms included <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, cardio-<span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, changes in the level of consciousness (ranging from <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and increased hepatic enzymes.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></p>
<p>There is no specific antidote to Savella, but if <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, treatment should consist of those general measures employed in the management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with any drug.</p>
<p>An adequate airway, oxygenation, and ventilation should be assured and cardiac rhythm and vital signs should be monitored. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Because there is no specific antidote for Savella, symptomatic care and treatment with gastric lavage and activated charcoal should be considered as soon as possible for patients who experience a Savella <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>Due to the large volume of distribution of this drug, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, dialysis, hemoperfusion, and exchange transfusion are unlikely to be beneficial.</p>
<p>In managing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the possibility of multiple drug involvement should be considered. The physician should consider contacting a poison control center for additional information on the treatment of any <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Telephone numbers for certified poison control centers are listed in the <span class="Italics">Physicians' Desk Reference</span> (PDR).</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s52"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Milnacipran hydrochloride is a selective norepinephrine and serotonin reuptake inhibitor; it inhibits norepinephrine uptake with greater potency than serotonin. It is a racemic mixture with the chemical name: (±)-[1R(S),2S(R)]-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride. The structural formula is:</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b3d078b-d12f-47ef-baa4-35b88b090ed4&amp;name=sav00-0004-01.jpg">
</div>
<p>Milnacipran hydrochloride is a white to off-white crystalline powder with a melting point of 179°C.</p>
<p>It is freely soluble in water, methanol, ethanol, chloroform, and methylene chloride and sparingly soluble in diethyl ether. It has an empirical formula of C15H23ClN2O and a molecular weight of 282.8 g/mol.</p>
<p>Savella is available for oral administration as film-coated tablets containing 12.5 mg, 25 mg, 50 mg, and 100 mg milnacipran hydrochloride. Each tablet also contains dibasic calcium phosphate, povidone, carboxymethylcellulose calcium, colloidal silicon dioxide, magnesium stearate, and talc as inactive ingredients. Additionally, the following inactive ingredients are also present as components of the film coat:</p>
<p>12.5 mg:</p>
<p>FD&amp;C Red #40 Aluminum Lake dye, hypromellose, polyethylene glycol, titanium dioxide</p>
<p>25 mg:</p>
<p>Hypromellose, polyethylene glycol, titanium dioxide</p>
<p>50 mg:</p>
<p>FD&amp;C Blue #1, Blue #2, and Yellow #5 Aluminum Lake dyes; hypromellose; polyethylene glycol; titanium dioxide</p>
<p>100 mg:</p>
<p>FD&amp;C Blue #1 Aluminum Lake dye, hypromellose, polyethylene glycol, titanium dioxide</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s53"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s54"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The exact mechanism of the central <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> inhibitory action of milnacipran and its ability to improve the symptoms of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> in humans are unknown. Preclinical studies have shown that milnacipran is a potent inhibitor of neuronal norepinephrine and serotonin reuptake; milnacipran inhibits norepinephrine uptake with approximately 3-fold higher potency in vitro than serotonin without directly affecting the uptake of dopamine or other neurotransmitters. Milnacipran has no significant affinity for serotonergic (5-HT1-7), α- and β-adrenergic, muscarinic (M1-5), histamine (H1-4), dopamine (D1-5), opiate, benzodiazepine, and γ-aminobutyric acid (GABA) receptors in vitro. Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs. Milnacipran has no significant affinity for Ca++, K+, Na+ and Cl– channels and does not inhibit the activity of human monoamine oxidases (MAO-A and MAO-B) or acetylcholinesterase.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s55"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Italics">Cardiovascular Electrophysiology</span>-The effect of Savella on the QTcF interval was measured in a double-blind placebo- and positive-controlled parallel study in 88 healthy subjects using 600 mg/day Savella (3 to 6 times the recommended therapeutic dose for <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>). After baseline and placebo adjustment, the maximum mean QTcF change was 8 ms (2-sided 90% CI, 3 - 12 ms). This increase is not considered to be clinically significant.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s56"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Milnacipran is well absorbed after oral administration with an absolute bioavailability of approximately 85% to 90%. The exposure to milnacipran increased proportionally within the therapeutic dose range. It is excreted predominantly unchanged in urine (55%) and has a terminal elimination half-life of about 6 to 8 hours. Steady-state levels are reached within 36 to 48 hours and can be predicted from single-dose data. The active enantiomer, <span class="Italics">d</span>-milnacipran, has a longer elimination half-life (8-10 hours) than the <span class="Italics">l</span>-enantiomer (4-6 hours). There is no interconversion between the enantiomers.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption and Distribution</span></p>
<p>Savella is absorbed following oral administration with maximum concentrations (Cmax) reached within 2 to 4 hours post dose. Absorption of Savella is not affected by food. The absolute bioavailability is approximately 85% to 90%. The mean volume of distribution of milnacipran following a single intravenous dose to healthy subjects is approximately 400 L.</p>
<p>Plasma protein binding is 13%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Elimination</span></p>
<p>Milnacipran and its metabolites are eliminated primarily by renal excretion. Following oral administration of <span class="Sup">14</span>C-milnacipran hydrochloride, approximately 55% of the dose was excreted in urine as unchanged milnacipran (24% as <span class="Italics">l</span>-milnacipran and 31% as <span class="Italics">d</span>-milnacipran). The <span class="Italics">l-</span>milnacipran carbamoyl-O-glucuronide was the major metabolite excreted in urine and accounted for approximately 17% of the dose; approximately 2% of the dose was excreted in urine as <span class="Italics">d-</span>milnacipran carbamoyl-O-glucuronide. Approximately 8% of the dose was excreted in urine as the N-desethyl milnacipran metabolite.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-12.4"></a><p></p>
<h2>12.4 Pharmacokinetics in Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-12.4.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>-Milnacipran pharmacokinetics were evaluated following single oral administration of 50 mg Savella to subjects with mild (creatinine clearance [CLcr] 50-80 mL/min), moderate (CLcr 30-49 mL/min), and severe (CLcr 5-29 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and to healthy subjects (CLcr &gt; 80 mL/min). The mean AUC0-∞ increased by 16%, 52%, and 199%, and terminal elimination half-life increased by 38%, 41%, and 122% in subjects with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, respectively, compared with healthy subjects.</p>
<p>No dosage adjustment is necessary for patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Caution should be exercised in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dose adjustment is necessary in severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> patients. [<span class="Italics">see Dosage and Administration (<a href="#s5">2.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-12.4.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>-Milnacipran pharmacokinetics were evaluated following single oral administration of 50 mg Savella to subjects with mild (Child-Pugh A), moderate (Child-Pugh B), and severe (Child-Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and to healthy subjects. AUC0-∞ and T½ were similar in healthy subjects and subjects with mild and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. However, subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had a 31% higher AUC0-∞ and a 55% higher T½ than healthy subjects. Caution should be exercised in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-12.4.3"></a><p></p>
<p class="First"><span class="Italics">Elderly</span>-Cmax and AUC parameters of milnacipran were about 30% higher in elderly (&gt; 65 years) subjects compared with young subjects due to age-related decreases in renal function. No dosage adjustment is necessary based on age unless renal function is severely impaired [<span class="Italics">see Dosage and Administration (<a href="#s5">2.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-12.4.4"></a><p></p>
<p class="First"><span class="Italics">Gender</span>-Cmax and AUC parameters of milnacipran were about 20% higher in female subjects compared with male subjects. Dosage adjustment based on gender is not necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-12.4.5"></a><p></p>
<p class="First"><span class="Italics">Drug-Drug Interactions</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-12.4.6"></a><p></p>
<p class="First"><span class="Italics">In Vitro Studies</span></p>
<p>In general, milnacipran, at concentrations that were at least 25 times those attained in clinical trials, did not inhibit human CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 or induce human CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4/5 enzyme systems, indicating a low potential of interactions with drugs metabolized by these enzymes.</p>
<p>In vitro studies have shown that the biotransformation rate of milnacipran by human hepatic microsomes and hepatocytes was low. A low biotransformation was also observed following incubation of milnacipran with cDNA-expressed human CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 isozymes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-12.4.7"></a><p></p>
<p class="First"><span class="Italics">In Vivo Studies</span></p>
<p>The drug interaction studies described in this section were conducted in healthy adult subjects.</p>
<p>Carbamazepine-There were no clinically significant changes in the pharmacokinetics of milnacipran following coadministration of Savella (100 mg/day) and carbamazepine (200 mg twice a day). No changes were observed in the pharmacokinetics of carbamazepine or its epoxide metabolite due to coadministration with Savella.</p>
<p>Clomipramine-Switch from clomipramine (75 mg once a day) to milnacipran (100 mg/day) without a washout period did not lead to clinically significant changes in the pharmacokinetics of milnacipran. Because an increase in adverse events (eg, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>) was observed after switching from clomipramine to milnacipran, monitoring of patients during treatment switch is recommended.</p>
<p>Digoxin-There was no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between Savella (200 mg/day) and digoxin (0.2 mg/day Lanoxicaps) following multiple-dose administration to healthy subjects.</p>
<p>Fluoxetine-Switch from fluoxetine (20 mg once a day), a strong inhibitor of CYP2D6 and a moderate inhibitor of CYP2C19, to milnacipran (100 mg/day) without a washout period did not affect the pharmacokinetics of milnacipran.</p>
<p>Lithium-Multiple doses of Savella (100 mg/day) did not affect the pharmacokinetics of lithium.</p>
<p>Lorazepam-There was no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between a single dose of Savella (50 mg) and lorazepam (1.5 mg).</p>
<p>Warfarin-Steady-state milnacipran (200 mg/day) did not affect the pharmacokinetics of R-warfarin and S-warfarin or the pharmacodynamics (as assessed by measurement of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> INR) of a single dose of 25 mg warfarin. The pharmacokinetics of Savella were not altered by warfarin.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s67"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s68"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Dietary administration of milnacipran to rats at doses of 50 mg/kg/day (2 times the MRHD on a mg/m<span class="Sup">2</span> basis) for 2 years caused a statistically significant increase in the incidence of thyroid C-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and combined <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas in males. A carcinogenicity study was conducted in Tg.rasH2 mice for 6 months at oral gavage doses of up to 125 mg/kg/day.</p>
<p>Milnacipran did not induce tumors in Tg.rasH2 mice at any dose tested.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis</span></p>
<p>Milnacipran was not mutagenic in the in vitro bacterial reverse mutation assay (Ames test) or in the L5178Y TK +/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay. Milnacipran was also not clastogenic in an in vitro chromosomal aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or in the in vivo mouse micronucleus assay.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span></p>
<p>Although administration of milnacipran to male and female rats had no statistically significant effect on mating or fertility at doses up to 80 mg/kg/day (4 times the MRHD on an mg/m<span class="Sup">2</span> basis) there was an apparent dose-related decrease in the fertility index at clinically relevant doses based on body surface area.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s72"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and Pharmacology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Bold">Hepatic Effects</span></p>
<p>Chronic administration (2-years) of milnacipran to rats at 15 mg/kg (0.6 times the MRHD on an mg/m<span class="Sup">2</span> basis) and higher doses showed increased incidences of centrilobular vacuolation of the liver in male rats and eosinophilic foci in male and female rats in the absence of any change in hepatic enzymes. The clinical significance of the finding is not known. Chronic (1-year) administration in the primate at doses up to 25 mg/kg (2 times the MRHD on a mg/m<span class="Sup">2</span> basis) did not demonstrate similar evidence of hepatic changes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Bold">Ocular Effects</span></p>
<p>Chronic (2-years) administration of milnacipran to rats at 15 mg/kg (0.6 times the MRHD on a mg/m<span class="Sup">2</span> basis) and higher doses showed increased incidence of <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> of the eye. One year studies in the rat and primate did not show this response.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s75"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></span></p>
<p>The efficacy of Savella for the management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> was established in two double-blind, placebo-controlled, multicenter studies in adult patients (18-74 years of age). Enrolled patients met the American College of Rheumatology (ACR) criteria for <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (a history of widespread <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> for 3 months and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> present at 11 or more of the 18 specific tender point sites). Approximately 35% of patients had a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Study 1 was six months in duration and Study 2 was three months in duration.</p>
<p>A larger proportion of patients treated with Savella than with placebo experienced a simultaneous reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline of at least 30% (VAS) and also rated themselves as much improved or very much improved based on the patient global assessment (PGIC). In addition, a larger proportion of patients treated with Savella met the criteria for treatment response, as measured by the composite endpoint that concurrently evaluated improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (VAS), physical function (SF-36 PCS), and patient global assessment (PGIC), in <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> as compared to placebo.</p>
<p>Study 1: This 6-month study compared total daily doses of Savella 100 mg and 200 mg to placebo. Patients were enrolled with a minimum mean baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of ≥ 50 mm on a 100 mm visual analog scale (VAS) ranging from 0 (“no pain?) to 100 (“worst possible pain?). The mean baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score in this trial was 69. The efficacy results for Study 1 are summarized in <a href="#f02">Figure 1</a>.</p>
<p><a href="#f02">Figure 1</a> shows the proportion of patients achieving various degrees of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline to the 3-month time point and who concurrently rated themselves globally improved (PGIC score of 1 or 2). Patients who did not complete the 3-month assessment were assigned 0% improvement. More patients in the Savella treatment arms experienced at least a 30% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline (VAS) and considered themselves globally improved (PGIC) than did patients in the placebo arm. Treatment with Savella 200 mg/day did not confer greater benefit than treatment with Savella 100 mg/day.</p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b3d078b-d12f-47ef-baa4-35b88b090ed4&amp;name=sav00-0004-02.jpg"><p class="MultiMediaCaption">Figure 1: Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief with Concurrent Ratings of Being Much or Very Much Improved on the PGIC - Study 1</p>
</div>
<p>Study 2: This 3-month study compared total daily doses of Savella 100 mg and 200 mg to placebo. Patients were enrolled with a minimum mean baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of ≥ 40 mm on a 100- mm VAS ranging from 0 (“no pain?) to 100 (“worst possible pain?). The mean baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score in this trial was 65. The efficacy results for Study 2 are summarized in <a href="#f03">Figure 2</a>.</p>
<p><a href="#f03">Figure 2</a> shows the proportion of patients achieving various degrees of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline to the 3-month time point and who concurrently rated themselves globally improved (PGIC score of 1 or 2). Patients who did not complete the 3-month assessment were assigned 0% improvement. More patients in the Savella treatment arms experienced at least a 30% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline (VAS) and considered themselves globally improved (PGIC) than did patients in the placebo arm. Treatment with Savella 200 mg/day did not confer greater benefit than treatment with Savella 100 mg/day.</p>
<div class="Figure">
<a name="f03"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b3d078b-d12f-47ef-baa4-35b88b090ed4&amp;name=sav00-0004-03.jpg"><p class="MultiMediaCaption">Figure 2: Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief with Concurrent Ratings of Being Much or Very Much Improved on the PGIC - Study 2</p>
</div>
<p>In both studies, some patients who rated themselves as globally “much? or “very much? improved experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as week 1 of treatment with a stable dose of Savella that persisted throughout these studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s77"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold Italics">12.5-mg tablets:</span></p>
<p>Blue, round, film-coated tablets, debossed with “F? on one side and “L? on the reverse
</p>
<p>Bottles of 60:               NDC 0456-1512-60
</p>
<p>10X10 Unit Dose:      NDC 0456-1512-63
</p>
<p><span class="Bold Italics">25-mg tablets:</span></p>
<p>White, round, film-coated tablets, debossed with “FL? on one side and “25? on the reverse
</p>
<p>Bottles of 60:              NDC 0456-1525-60
</p>
<p>Bottles of 180:            NDC 0456-1525-01
</p>
<p>10X10 Unit Dose:      NDC 0456-1525-63
</p>
<p><span class="Bold Italics">50-mg tablets:</span></p>
<p>White, oval-shaped, film-coated tablets, debossed with “FL? on one side and “50? on the reverse
</p>
<p>Bottles of 60:              NDC 0456-1550-60
</p>
<p>Bottles of 180:             NDC 0456-1550-01
</p>
<p>10X10 Unit Dose:      NDC 0456-1550-63
</p>
<p><span class="Bold Italics">100-mg tablets:</span></p>
<p>Pink, oval-shaped film-coated tablets, debossed with “FL? on one side and “100? on the reverse
</p>
<p>Bottles of 60:              NDC 0456-1510-60
</p>
<p>Bottles of 180:            NDC 0456-1510-01
</p>
<p>10X10 Unit Dose:      NDC 0456-1510-63
</p>
<p><span class="Bold Italics">Titration Pack:</span></p>
<p>4-Week Titration Pack:  NDC 0456-1500-55
</p>
<p><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> package containing 55 tablets: 5 x 12.5-mg tablets, 8 x 25-mg tablets, and 42 x 50 mg tablets.
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s78"></a><a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at 25°C (77°F); excursions permitted between 15°C and 30°C (between 59°F and 86°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s79"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"> See <a href="#s90">Medication Guide</a></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s80"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Information in Medication Guide</h2>
<p class="First">Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Savella and should counsel them in its appropriate use. A patient Medication Guide is available for Savella. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</p>
<p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Savella:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-16.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients and their families and caregivers should be advised that Savella is a selective norepinephrine and serotonin reuptake inhibitor and therefore belongs to the same class of drugs as antidepressants. Patients, their families and their caregivers should be advised that patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may be at increased risk for clinical worsening and/or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> if they stop taking anti-depressant medication, change the dose, or start a new medication.</p>
<p>Patients, their families and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> or other unusual changes in behavior, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during treatment with Savella or other drugs that inhibit the reuptake of norepinephrine and/or serotonin, and when the dose is adjusted up or down. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. [<span class="Italics">see <a href="#s1">Box Warning</a> and Warnings and Precautions (<a href="#s14">5.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s82"></a><a name="section-16.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with concomitant use of Savella and triptans, tramadol, or other serotonergic agents [<span class="Italics">see Warnings and Precautions (<a href="#s15">5.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s83"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Effect on Blood Pressure and Pulse</h2>
<p class="First">Patients should be advised that their blood pressure and pulse should be monitored at regular intervals when receiving treatment with Savella [<span class="Italics">see Warnings and Precautions (<a href="#s16">5.3</a>, <a href="#s17">5.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s84"></a><a name="section-16.5"></a><p></p>
<h2>17.5 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Patients should be cautioned about the concomitant use of Savella and NSAIDs, aspirin, or other drugs that affect coagulation, since the combined use of agents that interfere with serotonin reuptake and these agents has been associated with an increased risk of abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> [<span class="Italics">see Warnings and Precautions (<a href="#s22">5.9</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s85"></a><a name="section-16.6"></a><p></p>
<h2>17.6 Ability to Drive and Use Machinery</h2>
<p class="First">Savella might diminish mental and physical capacities necessary to perform certain tasks such as operating machinery, including motor vehicles. Patients should be cautioned about operating machinery or driving motor vehicles until they are reasonably certain that Savella treatment does not affect their ability to engage in such activities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s86"></a><a name="section-16.7"></a><p></p>
<h2>17.7 Alcohol</h2>
<p class="First">Patients should be advised to avoid consumption of alcohol while taking Savella [<span class="Italics">see Warnings and Precautions (<a href="#s19">5.6</a>, <a href="#s26">5.13</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s87"></a><a name="section-16.8"></a><p></p>
<h2>17.8 Discontinuation</h2>
<p class="First">Patients should be advised that withdrawal symptoms can occur when discontinuing treatment with Savella, particularly when discontinuation is abrupt. [<span class="Italics">see Warnings and Precautions (<a href="#s20">5.7</a>)</span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s88"></a><a name="section-16.9"></a><p></p>
<h2>17.9 Pregnancy</h2>
<p class="First">Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during Savella therapy [<span class="Italics">see Use in Specific Populations (<a href="#s39">8.1</a>)</span>].</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Patients should be encouraged to enroll in the Savella Pregnancy Registry if they become pregnant, preferably before any prenatal testing is done. This registry is collecting information about the safety of milnacipran during pregnancy. To enroll, patients or their healthcare providers may call the toll free number <span class="Underline">1-877-643-3010</span> [see Use in Specific Populations (<a href="#s39">8.1</a>)], download data forms from our website, www.savellapregnancyregistry.com, or email the registry for further information at registries@kendle.com.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s89"></a><a name="section-16.10"></a><p></p>
<h2>17.10 Nursing</h2>
<p class="First">Patients should be advised to notify their physician if they are breast-feeding [<span class="Italics">see Use in Specific Populations (<a href="#s43">8.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s90"></a><a name="section-16.11"></a><p></p>
<h2>17.11 FDA-Approved Medication Guide</h2>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="e90"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>Savella<span class="Sup">®</span> (Sa-vel-la) Tablets<br>(milnacipran HCl)</span></p>
<p><span class="Bold">Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other serious Mental Illnesses, and Suicidal<br>Thoughts or Actions</span></p>
<p>Savella is not used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, but it acts like medicines that are used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (antidepressants) and other psychiatric disorders.</p>
<p>Read the Medication Guide that comes with you or your family member's antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts or actions with antidepressant medicines. <span class="Bold">Talk to your or your family member's healthcare provider about:</span></p>
<ul class="Disc">
<li><span class="Bold">all risks and benefits of treatment with antidepressant medicines</span></li>
<li><span class="Bold">all treatment choices for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other serious mental illness</span></li>
</ul>
<p><span class="Bold">What is the most important information I should know about antidepressant medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other serious mental illnesses, and suicidal thoughts or actions?</span></p>
<ol class="Arabic">
<li><span class="Bold"> Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.</span></li>
<li>
<span class="Bold"> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions.</span> These include people who have (or have a family history of) bipolar illness (also called manicdepressive illness) or suicidal thoughts or actions.</li>
<li>
<span class="Bold"> How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?</span><ul class="Disc">
<li>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.</li>
<li>Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.</li>
<li>Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.</li>
</ul>
</li>
</ol>
<p><span class="Bold">Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span></p>
<a name="i747196fb-c2f4-48ed-8b25-175681b1dc58"></a><table width="100%">
<col align="left" width="44.600%">
<col align="left" width="55.400%">
<tbody class="Headless"><tr class="First Last">
<td align="left" valign="top"><ul class="Disc">
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></li>
<li>feeling very <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
</ul></td>
<td align="left" valign="top"><ul class="Disc">
<li>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</li>
<li>other unusual changes in behavior or mood</li>
<li>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">What else do I need to know about antidepressant medicines?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Never stop an antidepressant medicine without first talking to a healthcare provider.</span> Stopping an antidepressant medicine suddenly can cause other symptoms.</li>
<li>
<span class="Bold">Antidepressants are medicines used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other illnesses.</span> It is important to discuss all the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.</li>
<li>
<span class="Bold">Antidepressant medicines have other side effects.</span> Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.</li>
<li>
<span class="Bold">Antidepressant medicines can interact with other medicines.</span> Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.</li>
<li>
<span class="Bold">Not all antidepressant medicines prescribed for children are FDA approved for use in children.</span> Talk to your child's healthcare provider for more information. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA- 1088.</li>
</ul>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Revised: January 2009</span></p>
<p>Manufactured for:<br>Forest Pharmaceuticals, Inc.<br>Manufactured by:<br>Forest Laboratories, Inc.</p>
<p>Licensed from Pierre Fabre Medicament and Cypress Bioscience, Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PACKAGE LABEL</h1>
<p class="First">SAVELLA 25MG LABEL IMAGE</p>
<p><img alt="SAVELLA 25MG LABEL IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b3d078b-d12f-47ef-baa4-35b88b090ed4&amp;name=SAVELLA%2025MG%20LABEL%20845.jpg"></p>
<p>SAVELLA 50MG LABEL IMAGE</p>
<p><img alt="SAVELLA 50MG LABEL IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b3d078b-d12f-47ef-baa4-35b88b090ed4&amp;name=SAVELLA%2050MG%20LABEL%20846.jpg"></p>SAVELLA 100MG LABEL IMAGE<br><p><img alt="SAVELLA 100MG LABEL IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9b3d078b-d12f-47ef-baa4-35b88b090ed4&amp;name=SAVELLA%20100MG%20LABEL%20847.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SAVELLA 		
					</strong><br><span class="contentTableReg">milnacipran hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-845(NDC:0456-1525)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MILNACIPRAN HYDROCHLORIDE</strong> (MILNACIPRAN) </td>
<td class="formItem">MILNACIPRAN HYDROCHLORIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">FL;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-845-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-845-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-845-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022256</td>
<td class="formItem">04/17/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SAVELLA 		
					</strong><br><span class="contentTableReg">milnacipran hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-846(NDC:0456-1550)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MILNACIPRAN HYDROCHLORIDE</strong> (MILNACIPRAN) </td>
<td class="formItem">MILNACIPRAN HYDROCHLORIDE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 5</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">FL;50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-846-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-846-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-846-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022256</td>
<td class="formItem">04/17/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SAVELLA 		
					</strong><br><span class="contentTableReg">milnacipran hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-847(NDC:0456-1510)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MILNACIPRAN HYDROCHLORIDE</strong> (MILNACIPRAN) </td>
<td class="formItem">MILNACIPRAN HYDROCHLORIDE</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">FL;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-847-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-847-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-847-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022256</td>
<td class="formItem">04/17/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT RX USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT RX USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2007f488-af03-4d97-b61c-f51541d117cf</div>
<div>Set id: 9b3d078b-d12f-47ef-baa4-35b88b090ed4</div>
<div>Version: 1</div>
<div>Effective Time: 20100709</div>
</div>
</div> <div class="DistributorName">STAT RX USA LLC</div></p>
</body></html>
